Disease activity and damage in juvenile idiopathic arthritis: Methotrexate era versus biologic era by Giancane, G. et al.
RESEARCH ARTICLE Open Access
Disease activity and damage in juvenile
idiopathic arthritis: methotrexate era versus
biologic era
Gabriella Giancane1,2* , Valentina Muratore3, Valentina Marzetti2, Neus Quilis2, Belen Serrano Benavente2,
Francesca Bagnasco2, Alessandra Alongi1,2, Adele Civino4, Lorenzo Quartulli5, Alessandro Consolaro1,2 and
Angelo Ravelli1,2,6
Abstract
Objective: To compare the long-term disease state, in terms of activity and damage, of children with juvenile
idiopathic arthritis (JIA) who had their disease onset in methotrexate (MTX) or biologic eras.
Methods: Patients were included in MTX or biologic era cohort depending on whether their disease presentation
occurred before or after January 2000. All patients had disease duration ≥ 5 years and underwent a prospective
cross-sectional assessment, which included measurement of disease activity and damage. Inactive disease (ID) and
low disease activity (LDA) states were defined according to Wallace, JADAS10, and cJADAS10 criteria. Articular and
extraarticular damage was assessed with the Juvenile Arthritis Damage Index (JADI).
Results: MTX and biologic era cohorts included 239 and 269 patients, respectively. Patients were divided in the
“functional phenotypes” of oligoarthritis and polyarthritis. At cross-sectional visit, patients in the biologic era cohort
with either oligoarthritis or polyarthritis had consistently higher frequencies of ID and LDA by all criteria. The
measurement of disease damage at cross-sectional visit revealed that the frequency of impairment of > 1 JADI-
Articular items was higher in MTX than in biologic era cohort (17.6% versus 11% in oligoarthritis and 52.6% versus
21.8% in polyarthritis). Likewise, frequency of involvement of > 1 JADI-Extraarticular items was higher in the MTX
than in the biologic era cohort (26.5% versus 16.2% in oligoarthritis and 31.4% versus 13.5% in polyarthritis).
Conclusion: Our study provides evidence of the remarkable outcome improvement obtained with the recent
therapeutic advance in JIA.
Keywords: Juvenile idiopathic arthritis, Disease activity, Disease damage, Long-term outcome, Methotrexate,
Biologic agents
Introduction
Over the past three decades, the management of juvenile
idiopathic arthritis (JIA) has evolved considerably.
Historically, the therapeutic advance in this disease has
been marked by two major breakthroughs: the first was
represented by the introduction of methotrexate (MTX)
in the mid of the 1980s; the second, which took place in
the 2000s, was brought by the marketing of biologic
disease-modifying antirheumatic drugs (DMARDs). Owing
to their profound impact on therapeutic approaches and
disease prognosis, these two periods could be labeled as
“MTX era” and “biologic era”, respectively [1, 2].
The efficacy of MTX in JIA was initially suggested by
Truckenbrodt and co-workers in 1986 [3] and was then
established in a US-former USSR collaborative rando-
mized controlled trial (RCT) published in 1992 [4].
Based on these achievements, MTX became shortly the
DMARD of choice in JIA. A subsequent multinational
RCT conducted by the Paediatric Rheumatology Inter-
national Trials Organization (PRINTO) concluded that the
plateau of efficacy of MTX is reached with parenteral
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administration of 15mg/m2 per week (the maximum
weekly dose being 20mg/m2) [5]. In the same epoch, the
widespread use of MTX was paralleled by the growing
popularity of intraarticular corticosteroid therapy [6]. This
therapeutic procedure was initially used only for the knees,
but was then applied to other joints and performed repea-
tedly [7, 8]. Several outcome studies published in the early
2000s documented improved outlook for children with JIA
in the MTX era as compared to previous decades [9–11].
The first biologic DMARD studied in JIA was etaner-
cept. Its effectiveness and acceptable safety profile were
established in a RCT based on the withdrawal design,
published in 2000, in patients with polyarticular-course
JIA who were refractory or intolerant to MTX [12]. Over
the following years, three other anti-tumor necrosis factor
(TNF) agents (infliximab [13], adalimumab [14], and goli-
mumab [15]) were tested in RCTs in patients with poly-
articular course with JIA and a trial with another TNF-
blocking agent (certolizumab pegol) is currently being per-
formed [16]. In 2008, abatacept, another biologic DMARD
with a different mechanism of action, was registered for
use in the same disease subset [17]. Other RCTs estab-
lished the effectiveness and tolerability of the IL-6 inhibi-
tor tocilizumab [18, 19] and the anti-IL-1 agents anakinra
[20], canakinumab [21], and rilonacept [22, 23] in systemic
JIA. The sustained efficacy and high retention rate of most
of these agents was demonstrated in long-term extension
surveys of the original RCTs [24–26].
In recent years, the therapeutic aim has been increas-
ingly moved toward the evaluation of novel strategies
based on early aggressive interventions. Altogether, these
approaches were found to lead to clinical inactive disease
in a substantial proportion of patients with all phenotypes
of JIA [27–30]. A further improvement in disease out-
comes will likely be obtained with the implementation of
the treat-to-target strategy [31]. After nearly two decades
from the start of the biologic era, systematic analyses of
patient series treated with contemporary therapies have
shown a high frequency of attainment of inactive disease
and satisfactory levels of physical function and quality of
life [32–35]. However, the outcomes for children with JIA
treated the biologic or MTX eras have seldom been com-
pared. This question was addressed in the present study,
which was aimed to compare the long-term status in
terms of disease activity and damage of two cohorts of
children with JIA, one with disease onset in the MTX era
and one with disease onset in the biologic era.
Methods
Study design and patient selection
Based on the above-described timeline, we included in the
MTX era cohort patients with disease onset between
January 1986 and December 1999, and in the biologic era
cohort patients with disease onset after January 2000.
Patients in the MTX era cohort and part of the
patients in the biologic era cohort were taken from a
previous cross-sectional study published by our group
[11], which was aimed to evaluate the disease status of a
consecutive sample of JIA patients with a minimum
disease duration of 5 years who underwent a cross-
sectional assessment between 2002 and 2006. This in-
vestigation enrolled 310 patients who had a disease
duration of ≥ 5 years and a disease onset between
December 1986 and December 2002. Patients in this
study were placed in the MTX or biologic era cohort
depending on whether they had their disease onset before
or after January 2000, respectively.
An additional sample of patients with onset in the
biologic era was enrolled in a subsequent prospective
cross-sectional study, which included all consecutive
patients meeting the International League of Associations
for Rheumatology (ILAR) criteria for JIA [36] who were
seen consecutively at the Istituto G. Gaslini of Genoa,
Italy, between January 2015 and June 2017, had a disease
duration of ≥ 5 years and a disease onset between January
2002 and June 2011.
Levels of disease activity and damage could be com-
pared across patients included in the two studies as these
two constructs were assessed using the same clinical
instruments. Cross-sectional assessment was performed in
all patients at the last follow-up visit.
Patients with enthesitis-related arthritis had been
excluded from our previous cross-sectional study [11]
and were, therefore, not included also in the subsequent
prospective cross-sectional study.
All parents/guardians or patients (as appropriate) pro-
vided informed consent to participation in the study.
The study protocol was approved by the Ethics Commit-
tee of the Istituto G. Gaslini, Genoa, Italy.
Clinical assessment
At study visit, the following information was obtained for
each patient by reviewing clinical charts: sex, age at
disease onset, ILAR category, disease duration, age at
study visit, ANA status, and previous and present thera-
pies with synthetic and biologic DMARDs and systemic
and intraarticular glucocorticoids.
The following clinical assessments were made by the
attending pediatric rheumatologist: physician global
assessment of overall disease activity, measured on a
21-numbered circle visual analog scale (VAS; where
0 = no activity and 10 = maximum activity), and count
of joints with active arthritis, as described [37]. Laboratory
tests included erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP).
Prior to the study visit, a parent of each child was
asked to make a global assessment of child’s wellbeing
on a 21-numbered circle VAS (where 0 = very good and
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10 = very poor) and to rate the intensity of child’s pain
on a 21-numbered circle VAS (where 0 = no pain and
10 = very severe pain).
Assessment of disease activity
The level of disease activity was computed by means of
the Juvenile Arthritis Disease Activity Score 10
(JADAS10) [38] and its clinical (3-item) version, the
cJADAS10 [39, 40]. Briefly, the JADAS10 is composed of
the following four variables: (1) physician global assess-
ment of overall disease activity, (2) parent global assess-
ment of child’s wellbeing, (3) 10-joint reduced active
joint count, and (4) ESR. The JADAS10 is calculated as
the sum of the scores of its individual components,
which yields a global score of 0–40. The cJADAS10 has
the same structure of the JADAS10, but lacks the acute
phase reactant. Its score ranges from 0 to 30.
Inactive disease (ID) was defined by Wallace, JADAS10,
and cJADAS10 criteria [40–42]. By Wallace criteria, ID is
established if a patient has no joints with active arthritis,
no systemic manifestations attributable to JIA, no evi-
dence of active uveitis, normal acute-phase reactants, and
a physician global assessment indicating no disease
activity. The state of ID by both JADAS10 and cJADAS10
criteria is established if the score is ≤ 1 in either oligo-
arthritis and polyarthritis.
Low (or minimal) disease activity (LDA) was defined
by JADAS10 and cJADAS10 criteria [40, 42]. By these
criteria, LDA is established when the JADAS10 and cJA-
DAS10 are comprised between 1.1 and 2.0 and between
1.1 and 1.5, respectively, in oligoarthritis, and between
1.1 and 3.8 and between 1.1 and 2.5, respectively, in
polyarthritis [43].
Assessment of JADAS was not included in our previ-
ous study [11] because this tool was developed after its
publication. However, we could calculate both JADAS10
and cJADAS10 for all patients included in that study be-
cause all individual items were available in the database.
Assessment of disease damage
The amount of articular and extraarticular damage was
assessed through the Juvenile Arthritis Damage Index
(JADI) [44]. Briefly, the JADI is composed in two parts:
one devoted to the assessment of articular damage
(JADI-A), and one devoted to the assessment of extra-
articular damage (JADI-E). In the JADI-A, 36 joints or
joint groups are assessed for the presence of damage, and
the damage observed in each joint is scored on a 3-point
scale (where 0 = no damage, 1 =moderate damage, and
2 = severe damage, ankylosis, or prosthesis). The ma-
ximum total score is 72. The JADI-E includes 13 items in
5 different organs/systems. Each item is scored as 0 if
damage is absent or as 1 if damage is present. Due to the
relevant impact of ocular damage on the child’s health, in
each eye a score of 2 is given in case the patient has had
ocular surgery, and a score of 3 is given in case the patient
has developed legal blindness. The maximum total
score is 17.
Statistical analysis
Descriptive statistics are reported as median and inter-
quartile range (IQR) for continuous variables and as abso-
lute frequency and percentage for categorical variables.
Comparisons of disease characteristics between patient
groups were performed by means of the Mann-Whitney
U test in the case of quantitative data and by means of the
chi-square test, or Fisher’s exact test, as appropriate, in the
case of categorical data. To search for factors associated
with development of disease damage, we performed a
multivariable logistic regression analysis, including the
demographic and clinical features of both patient cohorts
as explanatory variables and the presence of articular or
extraarticular damage (i.e., JADI-A or JADI-E > 0) as an
outcome variable.
The statistical packages were SAS 9.3 (Institute Inc.,
Cary, NC, USA) and Statistica (version 8.0, StatSoft
Corp., Tulsa, OK, USA).
Results
The demographic and clinical features of the 239
patients included in the MTX era cohort and of the 269
patients included in the biologic era cohort are
presented in Table 1. Of the 310 patients enrolled in our
previous study [11], 239 were placed in the MTX era
cohort and 71 in the biologic era cohort as per the above
criteria. The two cohorts were comparable for the male-
to-female ratio and the frequency of antinuclear anti-
body positivity. Compared with the MTX era cohort, the
biologic era cohort had, on average, a younger onset age
and a longer disease duration at cross-sectional visit and
included a lower proportion of patients with systemic
and psoriatic arthritis and a greater proportion of
patients with oligoarthritis. Because the disproportionate
distribution of ILAR categories could affect the outcome
figures, we assessed all study outcomes by dividing
patients in the two “functional phenotypes” of oligo-
arthritis and polyarthritis. Patients were classified as
having oligoarthritis or polyarthritis if they had involve-
ment of 4 or less joints or 5 or more joints, respectively,
in the whole disease course, irrespective of their indivi-
dual ILAR category.
The medications administered before cross-sectional
visit and at the time of the visit are listed in Table 1. As
expected, the biologic era cohort had received much
more frequently biologic DMARDs than the MTX era
cohort. Use of systemic glucocorticoids was equal in the
two cohorts, whereas MTX and intraarticular gluco-
corticoids were given more commonly to patients in the
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biologic era cohort. At cross-sectional visit, more
patients in the MTX era cohort were receiving MTX,
whereas more patients in the biologic era cohort were
on biologic DMARDs. Very few patients in both cohorts
were taking systemic glucocorticoids. The percentage of
patients who were given a biologic DMARD in the past
and had been switched to a different biologic DMARD
for inefficacy or intolerance was 22.2% (22/99) in the
biologic era cohort and 7.7% (2/26) in the MTX era
cohort. The comparison of disease activity states at
cross-sectional visit between the two cohorts is shown in
Table 2. Compared with patients in the MTX era cohort,
patients in the biologic era cohort with either oligoarthritis
or polyarthritis had consistently higher frequencies of ID
and LDA by all criteria. Similar findings were seen for the
comparison of the individual physician-centered and
parent-reported outcomes, whose values were more
commonly at the zero end of the scale in the biologic era
cohort. Depending on the definition used, the proportion
of patients with ID who were receiving no treatment was
41.7–42.9% and 28.6–31.6% in the oligoarthritis and
polyarthritis category, respectively, in the MTX era
Table 1 Clinical characteristics at cross-sectional visit of patients in MTX and biologic era cohorts
MTX era (n = 239) Biologic era (n = 269) P
Female 189 (79.1) 219 (81.4) 0.51
Median (IQR) age at disease onset, years 3.1 (1.8–5.8) 2.5 (1.6–4.7) 0.016
Median (IQR) disease duration at study visit, years 7.7 (6.1–10.2) 6.9 (5.4–9.7) 0.0005
Median (IQR) disease duration at first observation, years 0.7 (0.2–2.0) 0.6 (0.2–1.8) 0.52
ILAR category
Systemic arthritis 23 (9.6) 17 (6.3) 0.0025
RF-negative polyarthritis 49 (20.5) 51 (19.0)
RF-positive polyarthritis 5 (2.1) 0.0 (0.0)
Persistent oligoarthritis 73 (30.5) 119 (44.2)
Extended oligoarthritis 55 (23.0) 63 (23.4)
Psoriatic arthritis 15 (6.3) 7 (2.6)
Undifferentiated arthritis 19 (7.9) 12 (4.5)
Patients with positive ANA 184 (77.0) 221 (82.2) 0.05
Past treatment
Methotrexate 153 (64.0) 209 (77.7) 0.0007
Cyclosporin A 58 (24.3) 19 (7.0) < 0.0001
Sulfasalazine 17 (7.1) 7 (2.6) 0.017
Biologic DMARDs 26 (10.9) 99 (36.8) < 0.0001
Etanercept 23 (9.6) 84 (31.2) < 0.0001
Infliximab 5 (2.1) 4 (1.5) 0.74
Adalimumab – 27 (10.0) –
Anakinra – 7 (2.6) –
Abatacept – 3 (1.1) –
Tocilizumab – 4 (1.5) –
Systemic glucocorticoids 92 (38.5) 85 (31.6) 0.10
Intraarticular glucocorticoids 187 (78.2) 250 (93.0) < 0.0001
Present treatment
Methotrexate 90/200 (45.0) 95/266 (35.7) 0.043
Cyclosporin A 18/200 (9.0) 3/266 (1.1) < 0.0001
Biologic DMARDs 16/200 (8.0) 89/266 (33.5) < 0.0001
Systemic glucocorticoids 8/200 (4.0) 8/266 (3.0) 0.56
No therapy 52/200 (26.0) 90/266 (33.8) 0.069
Data are number positive/number with information available (percentage) unless otherwise indicated; reference [11]
MTX methotrexate, IQR interquartile range, RF rheumatoid factor, ANA antinuclear antibodies, DMARDs disease antirheumatic drugs
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cohort, and 36.6–50.8% and 25–42.6% in the oligo-
arthritis and polyarthritis category, respectively, in the
biologic era cohort.
The measurement of disease damage at cross-sectional
visit revealed that the frequency of impairment of > 1
JADI-A items was higher in the MTX era cohort than in
the biologic era cohort (18/102, 17.6% versus 15/136,
11% in oligoarthritis and 72/137, 52.6% versus 29/133,
21.8% in polyarthritis). Likewise, the frequency of in-
volvement of > 1 JADI-E items was higher in the MTX
era cohort than in the biologic era cohort (27/102, 26.5%
versus 22/136, 16.2% in oligoarthritis and 43/137, 31.4%
versus 18/133, 13.5% in polyarthritis). Most individual
JADI items impaired in the MTX era cohort decreased
in frequency in the biologic era cohort, with reduction
in ocular damage in oligoarthritis being most notable.
The sole JADI items that were detected in more than 5%
of patients in the biologic era cohort were temporoman-
dibular damage in oligoarthritis and polyarthritis, ankle
damage in polyarthritis, and leg-length inequality in oli-
goarthritis (Table 3).
The lower frequency of articular and extraarticular
damage in the biologic era cohort was confirmed by
assessment by ILAR category (Figs. 1 and 2). To examine
the temporal trend of damage development over the 25
years of our analysis, we divided the study patients into
three groups by decade of disease onset (1986–1989,
1990–1999, 2000–2011). This evaluation, which is
depicted in Fig. 3, emphasized the marked decrease in
damage over time and the more pronounced decline in
the biologic era.
On multivariable logistic regression analysis, articular
damage was found to be more likely in the MTX era
cohort (versus the biologic era cohort; odds ratio (OR)
2.68, 95% confidence interval (CI) 1.72–4.15) and in
patients with polyarthritis (versus patients with oligo-
arthritis; OR 3.75, 95% CI 2.36–5.96), with older age at
disease onset (OR 1.07, 95% CI 1.0–1.14), and with
longer disease duration at study visit (OR 1.11, 95% CI
1.04–1.19). Extraarticular damage was more likely in the
MTX era cohort (versus the biologic era cohort; OR
2.52, 95% CI 1.62–3.92) and in patients with older age at
disease onset (OR 0.91, 95% CI 0.84–0.98).
The frequency of inactive disease and articular and
extraarticular damage in the 71 patients from our previous
study [11] diagnosed after 1999 and in the 198 patients in
the more recent cohort was comparable, which supported
their combination in a single group (result not shown).
Table 2 Frequency of clinical inactive disease and low disease activity parameters at cross-sectional visit of patients in MTX and
biologic era cohorts
MTX era (n = 239) Biologic era (n = 269) P
Oligoarthritis (n = 102) (n = 136)
Patients with physician global assessment = 0 34/100 (34.0) 85/134 (63.4) < 0.0001
Patients with active joint count = 0 33/102 (32.4) 90/136 (66.2) < 0.0001
Patients with parent global assessment = 0 37/96 (38.5) 61/114 (53.5) 0.0303
Patients with parent pain assessment = 0 39/95 (41.1) 65/122 (53.3) 0.074
Patients with ID by Wallace criteria 26/93 (28.0) 54/94 (57.4) < 0.0001
Patients with ID by JADAS10 24/85 (28.2) 41/78 (52.6) 0.0015
Patients with ID by cJADAS10 28/95 (29.5) 63/111 (56.8) < 0.0001
Patients with LDA by JADAS10 29/85 (34.1) 43/78 (55.1) 0.0070
Patients with LDA by cJADAS10 32/95 (33.7) 64/111 (57.7) 0.0010
Polyarthritis (n = 137) (n = 133)
Patients with physician global assessment = 0 25/132 (18.9) 76/133 (57.1) < 0.0001
Patients with active joint count = 0 25/136 (18.4) 78/133 (58.6) < 0.0001
Patients with parent global assessment = 0 33/127 (26.0) 53/113 (46.9) 0.0007
Patients with parent pain assessment = 0 38/125 (30.4) 58/118 (49.2) 0.0028
Patients with ID by Wallace criteria 19/129 (14.7) 48/98 (49.0) < 0.0001
Patients with ID by JADAS10 19/115 (16.5) 34/84 (40.5) 0.0002
Patients with ID by cJADAS10 21/122 (17.2) 54/112 (48.2) < 0.0001
Patients with LDA by JADAS10 33/115 (28.7) 52/84 (61.9) < 0.0001
Patients with LDA by cJADAS10 29/122 (23.8) 60/112 (53.6) < 0.0001
Data are number positive/number with information available (percentage); reference [11]
MTX methotrexate, ID inactive disease, LDA low disease activity, JADAS10 Juvenile Disease Activity Score 10, cJADAS Clinical Juvenile Disease Activity Score 10
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Discussion
We compared the rate of ID and LDA and the frequency
and distribution of articular and extraarticular damage
between two inception cohorts of JIA patients with
long-standing disease (i.e., with a disease duration ≥ 5
years) who had their disease onset during the “MTX
era” (i.e., between 1986 and 1999) or during the “biologic
era” (i.e., after 2000). We found that the states of ID and
LDA were achieved more frequently by patients in the
biologic era cohort and that this cohort also had a lower
frequency of cumulative damage in both articular and
extraarticular domains than the MTX era cohort. These
findings provide a demonstration that the recent thera-
peutic progresses have improved markedly the outlook
of children with JIA as compared to the pre-biologic era.
As expected, patients in the biologic era cohort had
received much more frequently biologic DMARDs than
patients in the MTX era cohort. However, the former
sample was also given more commonly MTX and intra-
articular glucocorticoids, which reflects the current shift to-
ward a more aggressive global therapeutic approach [45].
Systemic glucocorticoids were used in around 30% of pa-
tients in both cohorts, but at cross-sectional visit, only less
than 4% of the patients were still taking these medications.
Our findings in the biologic era cohort indicate that
more than 50% of patients with oligoarthritis and 40–50%
of patients with polyarthritis treated with contemporary
therapies may achieve ID over the long-term. A fur-
ther 5–10% reached the state of LDA, which is regarded
as a qualified and valid therapeutic goal, particularly in
patients with long-standing disease [31]. These figures are
not easily comparable with those reported in other recent
surveys because of differences in proportion of disease
categories, length of follow-up, outcome endpoints,
Table 3 Percentages of Juvenile Arthritis Damage Index (JADI) articular and extraarticular items by therapeutic era in patients with
oligoarthritis and polyarthritis
Oligoarthritis (n = 238) Polyarthritis(n = 270)
MTX era (n = 102) Biologic era (n = 136) MTX era (n = 137) Biologic era (n = 133)
Articular
Temporomandibular 7 (6.9) 10 (7.4) 16 (11.7) 13 (9.8)
Cervical spine 2 (2.0) 1 (0.7) 13 (9.5) 2 (1.5)
Shoulder 1 (1.0) 0 (0.0) 14 (10.2) 1 (0.8)
Elbow 3 (2.9) 1 (0.7) 27 (19.7) 1 (0.8)
Wrist 2 (2.0) 0 (0.0) 31 (22.6) 2 (1.5)
Metacarpophalangeal 1 (1.0) 1 (0.7) 15 (10.9) 3 (2.3)
Proximal interphalangeal 2 (2.0) 0 (0.0) 29 (21.2) 5 (3.8)
Hip 1 (1.0) 2 (1.5) 17 (12.4) 1 (0.8)
Knee 3 (2.9) 1 (0.7) 19 (13.9) 4 (3.0)
Ankle 5 (4.9) 2 (1.5) 13 (9.5) 8 (6.0)
Metatarsophalangeal 0 (0.0) 0 (0.0) 20 (14.6) 2 (1.5)
Extraarticular
Ocular 13 (12.7) 1 (0.7) 8 (5.8) 6 (4.5)
Muscular atrophy 6 (5.9) 6 (4.4) 13 (9.5) 2 (1.5)
Osteoporosis 1 (1.0) 0 (0.0) 2 (1.5) 1 (0.8)
Avascular necrosis 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8)
Scoliosis 6 (5.9) 4 (2.9) 11 (8.0) 1 (0.8)
Leg length inequality 9 (8.8) 15 (11.0) 9 (6.6) 6 (4.5)
Striae rubrae 0 (0.0) 0 (0.0) 3 (2.2) 1 (0.8)
Subcutaneous atrophy 4 (3.9) 1 (0.7) 5 (3.6) 5 (3.8)
Growth failure 2 (2.0) 0 (0.0) 17 (12.4) 1 (0.8)
Pubertal delay 0 (0.0) 0 (0.0) 5 (3.6) 0 (0.0)
Diabetes 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Amyloidosis 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Others 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0)
Data are number positive/number with information available (percentage) unless otherwise indicated; reference [11]
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treatments, and statistical methodology. In a multicenter
Canadian study of 1104 children with JIA, Guzman and
co-workers [46] found that the cumulative probability of
attaining disease remission within 5 years was 46–57%
across JIA categories, except for rheumatoid factor (RF)-
positive and RF-negative polyarthritis, whose probability
was 0% and 14%, respectively. Of a British cohort of 1415
children and adolescents with JIA, between 48% and 61%
achieved MDA and between 25% and 38% achieved ID,
depending on the criteria used, at 1 year following pre-
sentation [47]. A German multicenter study of 695 JIA
patients found that at the 12-month follow-up 40% of
them had achieved a continuously ID for at least 3months
[48]. Boiu et al. [49] reported that 31% and 56% of 95
patients with a median disease duration of 3.5 years had
ID and LDA, respectively.
The improvement in disease prognosis from the MTX to
the biologic era was also underscored by the marked
decrease over time in the frequency of articular and extra-
articular damage. Most of the JADI items that were
impaired in the MTX era cohort were less frequently
affected in the biologic era cohort, with the most notable
improvement being the reduction in ocular sequelae in the
oligoarthritis group. There were, however, some forms of
damage whose impact was not diminished in the biologic
era cohort, which included temporomandibular and ankle
alterations and leg-length inequality. The unchanged preva-
lence of temporomandibular joint damage may depend on
the frequent paucity of symptoms in temporomandibular
joint arthritis, which may lead to delayed diagnosis and late
institution of appropriate therapy [50]. The ankle is a
complex anatomic area, which comprises several individual
Fig. 2 Percentage of patients with extraarticular damage (i.e., JADI-E > 0) by JIA category in the two study cohorts
Fig. 1 Percentage of patients with articular damage (i.e., JADI-A > 0) by JIA category in the two study cohorts
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joints (tibio-crural, subtalar, and intertarsal) and a number
of tendons, all of which can become inflamed. For this rea-
son, complete control of ankle arthritis may prove difficult.
Notably, ankle involvement has been found to be associated
with poorer prognosis and with a lesser response to
intra-articular glucocorticoid therapy in JIA [51, 52].
The continued occurrence of leg-length discrepancy,
which is a well-known consequence of knee mono-
arthritis, emphasizes the need of timely intra-articular
glucocorticoid injection in this joint, a procedure that
may prevent this complication [53].
Our analysis should be interpreted in the light of some
caveats. Because the study was conducted in Western
pediatric rheumatology centers, its results may not be
generalizable, particularly to geographic settings where the
costly biologic medications may not be available or afford-
able [54]. We focused on disease-centered measures of dis-
ease activity and damage and did not assess physical
function and health-related quality of life. Studies in recent
series have shown that the majority of JIA patients have
normal or near-normal functional ability and achieve a
health-related quality of life that is similar to that of healthy
peers [49, 55]. Outcome endpoints did not include imaging
procedures, which could provide a more objective esti-
mation than clinical tools. We only examined the rate of ID
at a single point in time and did not evaluate its duration,
which could have allowed us to calculate the rate of clinical
remission on and off medications [56]. The inability to
calculate the percentage of patients who failed the first
DMARD did not allow us to assess the time spent before
the achievement disease control, which may influence the
prognosis. In addition, we could not evaluate the propor-
tion of patients who achieved remission in less than 5 years
and were, then, lost to follow-up. The differences in the
frequency of disease activity and damage between the two
cohorts could have been affected by the disparity in age at
onset, disease duration, and proportion of JIA categories.
Some patients in the MTX era cohort had received biologic
DMARDs, which could represent a confounding factor.
However, it is likely that most of these patients had started
biologics later and were given an overall less aggressive
treatment than patients in the biologic era cohort, in line
with the aforementioned shift in the therapeutic paradigm
between the two eras. We should finally acknowledge that
there were no patients with RF-positive polyarthritis in the
biologic era cohort and that only 2% patients in the MTX
era sample had this disease category. The low pro-
portion of patients with RF-positive polyarthritis, which
is one of the most severe forms of JIA, could have in-
fluenced the results.
In conclusion, our study provides evidence from stand-
ard clinical care of the remarkable prognostic improve-
ment obtained with the recent therapeutic advance in JIA.
However, there is still a sizeable proportion of patients
who do not achieve complete disease quiescence with
contemporary therapies. In addition, some important
Fig. 3 Percentage of patients with articular damage (i.e., JADI-A > 0) and extraarticular damage (i.e., JADI-E > 0) over 25 years in the study patients
divided by decade of disease onset
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sources of damage, such as temporomandibular and ankle
joint damage and leg-length inequality, remain prevalent.
These findings underscore the need for newer treatments
and treatment strategies that have the ability to better
control disease activity in the most resistant cases and to
further reduce the development of disease damage.
Abbreviations
ANA: Antinuclear antibodies; CRP: C-reactive protein; DMARDs: Disease-
modifying antirheumatic drugs; ESR: Erythrocyte sedimentation rate; ID: Inactive
disease; ILAR: International League of Associations for Rheumatology;
JADAS: Juvenile Arthritis Disease Activity Score; JADI-A: Articular Juvenile
Arthritis Damage Index; JADI-E: Extraarticular Juvenile Arthritis Damage Index;
JIA: Juvenile idiopathic arthritis; LDA: Low disease activity; MTX: Methotrexate;
PRINTO: Paediatric Rheumatology INternational Trials Organization;
RCT: Randomized controlled trials; RF: Rheumatoid factor; TNF: Tumor necrosis
factor; VAS: Visual analog scale
Acknowledgements
We thank all centers that contributed to data collection.
Accession number to microarray data if applicable
Not applicable.
Clinical trial registration number and date if applicable
Not applicable.
Authors’ contributions
AR and GG have contributed to the development of the study and the
generation of the manuscript; GG, VM, VM, NQ, BSB, AA, AC, LQ, and AC
have contributed to data collection; FB and GG have contributed to the
statistical analysis. All authors read and approved the final manuscript.
Funding
No funding was available for this study.
Availability of data and materials
Patients in the MTX era cohort and part of the patients in the biologic
era cohort were taken from a previous cross-sectional study published
by our group [11].
Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of the Istituto G.
Gaslini, Genoa, Italy. All parents/guardians or patients (as appropriate) provided




AR has received grant support and/or speaking or consultant fees from
Angelini, AbbVie, Bristol-Myers Squibb, Johnson & Johnson, Novartis, Pfizer,
Reckitt Benkiser, and Roche; AC reports personal fees from Abbvie and non-
financial support from Pfizer; GG, VM, VM, NQ, BSB, AA, AC, and LQ declare
that they have no competing interests.
Author details
1Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e
Scienze Materno-Infantili, Università degli Studi di Genova, Genoa, Italy.
2Clinica Pediatrica e Reumatologia, IRCCS G. Gaslini, via G. Gaslini 5, 16147
Genoa, Italy. 3Clinica Pediatrica, IRCCS Fondazione Policlinico San Matteo,
Pavia, Italy. 4Ospedale Vito Fazzi, Lecce, Italy. 5UOC Pediatria, Azienda
Ospedaliera Cardinale G. Panico, Tricase, Italy. 6Sechenov First Moscow State
Medical University, Moscow, Russian Federation.
Received: 14 January 2019 Accepted: 24 June 2019
References
1. Lovell DJ. Ten years of experience with methotrexate. Past, present and
future. Rev Rhum Engl Ed. 1997;64(10Suppl:186S–8S.
2. Lovell DJ, Ruperto N, Giannini EH, Martini A. Advances from clinical trials in
juvenile idiopathic arthritis. Nat Rev Rheumatol. 2013;9:557–63.
3. Truckenbrodt H, Ha R. Methotrexate therapy in juvenile rheumatoid arthritis:
a retrospective study. Arthritis Rheum. 1986;29:801–7.
4. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink
CW, Newman AJ, Cassidy JTZL. Methotrexate in resistant juvenile
rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-
controlled trial. The Pediatric Rheumatology Collaborative Study Group and
The Cooperative Children’s Study Group. N Engl J Med. 1992;326:1043–9.
5. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral
methotrexate comparing an intermediate dose with a higher dose in
children with juvenile idiopathic arthritis who failed to respond to standard
doses of methotrexate. Arthritis Rheum. 2004;50:2191–201.
6. Malleson P, Petty R. Remodelling the pyramid--a pediatric prospective. J
Rheumatol. 1990;17:867–8.
7. Dent PB, Walker N. Intra-articular corticosteroids in the treatment of juvenile
rheumatoid arthritis. Curr Opin Rheumatol. 1998;10:475–80.
8. Scott C, Meiorin S, Filocamo G, et al. A reappraisal of intra-articular
corticosteroid therapy in juvenile idiopathic arthritis. Clin Exp Rheumatol.
2010;28:774-81.
9. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease
course and outcome of juvenile rheumatoid arthritis in a multicenter
cohort. J Rheumatol. 2002;29:1989–99.
10. Bowyer SL, Roettcher PA, Higgins GC, Adams B, Myers LK, Wallace C,
Rennebohm R, Moore TL, Pepmueller PH, Spencer C, Wagner-Weiner L,
Rabinovich E, Passo M, Lovell DJ, McCurdy D, Zemel L, Schikler KN, Szer I,
Kurtin PLC. Health status of patients with juvenile rheumatoid arthritis at 1
and 5 years after diagnosis. J Rheumatol. 2003;30:394–400.
11. Solari N, Viola S, Pistorio A, et al. Assessing current outcomes of juvenile
idiopathic arthritis: a cross-sectional study in a tertiary center sample.
Arthritis Care Res. 2008;59:1571–9.
12. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with Polyarticular
juvenile rheumatoid Arthritis. N Engl J Med. 2000;342:763–9.
13. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial
of infliximab plus methotrexate for the treatment of polyarticular-course
juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096–106.
14. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without
methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–20.
15. Brunner HI, Ruperto N, Tzaribachev N, et al. Subcutaneous golimumab for
children with active polyarticular-course juvenile idiopathic arthritis: results
of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis.
2017. https://doi.org/10.1136/annrheumdis-2016-210456.
16. US National Library of Medicine. ClinicalTrials.gov [online], http://www.
clinicaltrials.gov/ct2/show/NCT01230827 (2013).
17. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile
idiopathic arthritis: a randomised, double-blind, placebo-controlled
withdrawal trial. Lancet. 2008;372:383–91.
18. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab
in patients with systemic-onset juvenile idiopathic arthritis: a
randomised, double-blind, placebo-controlled, withdrawal phase III trial.
Lancet. 2008;371:998–1006.
19. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in
systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95.
20. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-
blind, placebo-controlled trial with the interleukin-1 receptor antagonist
anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS
trial). Ann Rheum Dis. 2011;70:747–54.
21. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of
Canakinumab in systemic juvenile idiopathic Arthritis. N Engl J Med.
2012;367:2396–406.
22. Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of
rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis
Rheum. 2013;65(9):2486–96.
23. Ilowite NT, Prather K, Lokhnygina Y, et al. Randomized, double-blind,
placebo-controlled trial of the efficacy and safety of rilonacept in the
Giancane et al. Arthritis Research & Therapy          (2019) 21:168 Page 9 of 10
treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol
(Hoboken, NJ). 2014;66:2570–9.
24. Giannini EH, Ilowite NT, Lovell DJ, et al. Effects of long-term etanercept
treatment on growth in children with selected categories of juvenile
idiopathic arthritis. Arthritis Rheum. 2010;62:3259–64.
25. Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H,
Murata T, Miyoshi M, Tomiita M, Nishimoto NKT. Long-term treatment of
systemic juvenile idiopathic arthritis with tocilizumab: results of an open-
label extension study in Japan. Ann Rheum Dis. 2013;72:627–8.
26. Ruperto N, Brunner HI, Quartier P, et al. Canakinumab in patients with
systemic juvenile idiopathic arthritis and active systemic features: results
from the 5-year long-term extension of the phase III pivotal trials. Ann
Rheum Dis. 2018;77:1710-19.
27. Ravelli A, Davì S, Bracciolini G, Pistorio A, Consolaro A, van Dijkhuizen EH,
Lattanzi B, Filocamo G, Verazza S, Gerloni V, Gattinara M, Pontikaki I, Insalaco
A, De Benedetti F, Civino A, Presta G, Breda L, Marzetti V, Pastore S, Magni-
AIPRSG. Intra-articular corticosteroids versus intra-articular corticosteroids
plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre,
prospective, randomised, open-label trial. Lancet. 2017;389:909–16.
28. Tynjala P, Vahasalo P, Tarkiainen M, et al. Aggressive combination drug
therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-
JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis.
2011;70:1605–12.
29. Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy
in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012-2021;64:2012.
30. Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line
treatment with recombinant interleukin-1 receptor antagonist in steroid-
naive patients with new-onset systemic juvenile idiopathic arthritis:
results of a prospective cohort study. Arthritis Rheumatol (Hoboken, NJ).
2014;66:1034–43.
31. Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, Akikusa
JD, Al-Mayouf SM, Antón J, Avcin T, Berard RA, Beresford MW, Burgos-Vargas
R, Cimaz R, De Benedetti F, Demirkaya E, Foell D, Itoh Y, Lahdenne PSJ.
Treating juvenile idiopathic arthritis to target: recommendations of an
international task force. Ann Rheum Dis. 2018;77:819–28.
32. Guzman J, Oen K, Tucker LB, et al. The outcomes of juvenile idiopathic
arthritis in children managed with contemporary treatments: results from
the ReACCh-out cohort. Ann Rheum Dis. 2015;74:1854–60.
33. Verazza S, Davì S, Consolaro A, et al. Disease status, reasons for
discontinuation and adverse events in 1038 Italian children with juvenile
idiopathic arthritis treated with etanercept. Pediatr Rheumatol. 2016;14:68.
34. Chang CY, Meyer RML, Reiff AO. Impact of medication withdrawal method
on flare-free survival in patients with juvenile idiopathic arthritis on
combination therapy. Arthritis Care Res (Hoboken). 2015;67:658–66.
35. Wulffraat. The value of old drugs for juvenile idiopathic arthritis. Lancet
(London, England). 2017;6736:1–2.
36. Petty RE, Southwood TR, Manners P, et al. International league of
associations for rheumatology classification of juvenile idiopathic arthritis:
second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.
37. Ravelli A, Viola S, Ruperto N, Corsi B, Ballardini G, Martini A. Correlation
between conventional disease activity measures in juvenile chronic arthritis.
Ann Rheum Dis. 1997;56:197–200.
38. Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a
composite disease activity score for juvenile idiopathic arthritis. Arthritis
Rheum. 2009;61:658–66.
39. McErlane F, Beresford MW, Baildam EM, et al. Validity of a three-variable
juvenile arthritis disease activity score in children with new-onset juvenile
idiopathic arthritis. Ann Rheum Dis. 2013;72:1983–8.
40. Consolaro A, Negro G, Chiara Gallo M, et al. Defining criteria for disease
activity states in nonsystemic juvenile idiopathic arthritis based on a three-
variable juvenile arthritis disease activity score. Arthritis Care Res (Hoboken).
2014;66:1703–9.
41. Wallace CA, Ruperto N, Giannini E, Arthritis C. Preliminary criteria for clinical
remission for select categories of juvenile idiopathic Arthritis re er d. J
Rheumatol. 2004;31:2290–4.
42. Consolaro A, Bracciolini G, Ruperto N, et al. Remission, minimal disease
activity, and acceptable symptom state in juvenile idiopathic arthritis:
defining criteria based on the juvenile arthritis disease activity score.
Arthritis Rheum. 2012;64:2366–74.
43. Consolaro A, Schiappapietra B, Dalprà S, Calandra S, Martini A, Ravelli A.
Optimisation of disease assessments in juvenile idiopathic arthritis. Clin Exp
Rheumatol. 2014;32:S126–30.
44. Viola S, Felici E, Magni-Manzoni S, et al. Development and validation of a
clinical index for assessment of long-term damage in juvenile idiopathic
arthritis. Arthritis Rheum. 2005;52:2092–102.
45. Wallace CA, Giannini EH, Spalding SJ, et al. Clinically inactive disease in a
cohort of children with new-onset polyarticular juvenile idiopathic arthritis
treated with early aggressive therapy: time to achievement, total duration,
and predictors. J Rheumatol. 2014;41:1163–70.
46. Guzman J, Oen K, Huber AM, et al. The risk and nature of flares in juvenile
idiopathic arthritis: results from the ReACCh-Out cohort. Ann Rheum Dis.
2016;75:1092–8.
47. Shoop-Worrall SJW, Verstappen SMM, Baildam E, et al. How common is
clinically inactive disease in a prospective cohort of patients with
juvenile idiopathic arthritis? The importance of definition. Ann Rheum
Dis. 2017;76:1381–8.
48. Sengler C, Klotsche J, Niewerth M, et al. The majority of newly diagnosed
patients with juvenile idiopathic arthritis reach an inactive disease state
within the first year of specialised care: data from a German inception
cohort. RMD Open. 2015 8;1(1):e000074.
49. Boiu S, Marniga E, Bader-Meunier B, et al. Functional status in severe
juvenile idiopathic arthritis in the biologic treatment era: an assessment in a
French paediatric rheumatology referral centre. Rheumatol (United
Kingdom). 2012;51:1285–92.
50. Arabshahi B, Cron RQ. Temporomandibular joint arthritis in juvenile
idiopathic arthritis: the forgotten joint. Curr Opin Rheumatol. 2006;18:490–5.
51. Felici E, Novarini C, Magni-Manzoni S, et al. Course of joint disease in
patients with antinuclear antibody-positive juvenile idiopathic arthritis. J
Rheumatol. 2005;32:1805–10.
52. Lanni S, Bertamino M, Consolaro A, et al. Outcome and predicting factors of
single and multiple intra-articular corticosteroid injections in children with
juvenile idiopathic arthritis. Rheumatology (Oxford). 2011;50:1627–34.
53. Sherry DD, Stein LD, Reed AM, et al. Prevention of leg length discrepancy in
young children with pauciarticular juvenile rheumatoid arthritis by
treatment with intraarticular steroids. Arthritis Rheum. 1999;42:2330–4.
54. Consolaro A, Ruperto N, Filocamo G, et al. Seeking insights into the
EPidemiology, treatment and outcome of childhood arthritis through a
multinational collaborative effort: introduction of the EPOCA study. Pediatr
Rheumatol Online J. 2012;10:39.
55. Listing M, Mönkemöller K, Liedmann I, et al. The majority of patients with
newly diagnosed juvenile idiopathic arthritis achieve a health-related quality
of life that is similar to that of healthy peers: results of the German
multicenter inception cohort (ICON). Arthritis Res Ther. 2018;20:1–12.
56. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College
of Rheumatology provisional criteria for defining clinical inactive disease
in select categories of juvenile idiopathic arthritis. Arthritis Care Res.
2011;63:929–36.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Giancane et al. Arthritis Research & Therapy          (2019) 21:168 Page 10 of 10
